Clinical trial
Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii…
NCT00002043 · Jacobus Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00002043 |
|---|---|
| Title | Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC) |
| Official title | Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC) |
| Lead sponsor | Jacobus Pharmaceutical, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Pneumonia, Pneumocystis Carinii, HIV Infections |
| Intervention type | Drug |
| Interventions | Dapsone |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: